Please ensure Javascript is enabled for purposes of website accessibility

Taking Inventory on Seattle Genetics, Inc. Earnings

By Brian Orelli, PhD - May 4, 2016 at 6:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Adcetris sales didn't grow as much as hoped, but management blames an inventory drawdown and other factors while sticking with full-year guidance.

Seattle Genetics (SGEN -0.89%) released first-quarter earnings results on Thursday, and while sales of Adcetris continued to grow, they weren't quite as robust as investors were hoping for. 

Seattle Genetics results: The raw numbers

 

Q1 2016 Actuals

Q1 2015 Actuals

Growth (YOY)

Revenue

$111.2 million

$82.2 million

35%

(Loss) from Operations

$(21.0 million)

$(21.7 million)

N/A

(Loss) Per Share

$(0.15)

$(0.17)

N/A


What happened with Seattle Genetics
 this quarter?

  • IMAGE SOURCE: SEATTLE GENETICS.

    Sales of Adcetris in the U.S. and Canada, where Seattle Genetics sells the drug, were up 20%, to $58.6 million.
  • Revenue was hurt by larger gross-to-net discounts because a higher proportion of purchases came from sites eligible for government discounts. There was also a little bit of a drawdown of inventory that built up in the fourth quarter ahead of actual demand.
  • Royalty revenue from Takeda in areas where the Japanese pharma sells Adcetris was up 11% year over year, not including a $20 million one-time payment for reaching annual net sales of $200 million in its territory during 2015.
  • Seattle Genetics expects top-line data from the ALCANZA trial testing Adcetris in cutaneous T-cell lymphoma in the third quarter of this year. (Previous guidance was for the second half of this year.)

What management had to say
Adcetris is Seattle Genetics' most-important asset because it generates revenue. However, investors shouldn't forget about the biotech's pipeline, especially SGN-CD33A, because it's ready to be tested in a trial that can be used to gain regulatory approval. As president and CEO Clay Siegall explained, "We are on track to advance 33A into a phase 3 registrational trial in frontline older patients with acute myeloid leukemia by the third quarter of this year."

There's also opportunity to expand Adcetris' sales substantially if the ongoing ECHELON-1 (E-1) trial is positive. "So we think that if you look at E-1 and the opportunity in frontline Hodgkin lymphoma, it is well in excess of $1 billion," Siegall said.

Looking forward
Management stuck by its guidance for Adcetris sales in U.S. and Canada between $255 million to $275 million. To hit that goal, sales will have to pick up from the $58.6 million in the first quarter. Presumably, factors like inventory drawdown won't be an issue in future quarters.

To increase sales substantially from there, Seattle Genetics needs to expand into other patients, so positive data from the aforementioned ALCANZA trial are critical. Further behind, ECHELON-1 trial in frontline Hodgkin lymphoma is set to read out sometime in 2017 through mid-2018, and data from the ECHELON-2 trial in mature T-cell lymphoma is expected in 2017 or 2018, depending on when it finishes enrolling patients.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$177.73 (-0.89%) $-1.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.